Microglia

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, April 2, 2024
8-K, Research, Cash, Prevalence, HNSCC, Patient, Biomarker, Microglia, Sale, Nature, Form 10-K, Cancer, Neuroinflammation, Neuron, Neoplasm, Cognition, Drug development, Head and neck cancer, Astrocyte, PFS, Security, Neurodegenerative disease, Pharmaceutical industry

ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on key programs.

Key Points: 
  • ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on key programs.
  • Vaccinex achieved several important clinical milestones for pepinemab in both Alzheimer’s disease and Head and Neck Cancer.
  • Financial Results for the Year Ended December 31, 2023:
    Cash and Cash Equivalents and Marketable Securities.
  • The Company effected a 1-for-15 reverse stock split in Q3 2023 and 1-for-14 reverse stock split in Q1 2024.

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 26, 2024
Research, Administration, CSF1R, TREM2, MRI, Data analysis, PD, CSF, Magnetic resonance imaging, Patient, Biomarker, Microglia, Osteopontin, Fluid mechanics, IGNITE, Investment, Clinical trial, Pharmacokinetics, Interim, Research and development, Data, FDA, AFL, Pharmaceutical industry

WATERTOWN, Mass., March 26, 2024 (GLOBE NEWSWIRE) --  Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent progress.

Key Points: 
  • “Among our many recent milestones, the most significant for Vigil was the positive data readout from our ongoing Phase 2 IGNITE trial and ILLUMINATE Natural History Study.
  • We are also pleased to have enrolled 20 patients in our IGNITE trial, exceeding our target of 15 patients.
  • Cash Position: Cash, cash equivalents, and marketable securities were $117.9 million as of December 31, 2023, compared to $133.6 million as of September 30, 2023.
  • The increase year-over-year was primarily attributable to increases in headcount-related costs and professional service fees to support the Company’s growth.

Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, March 20, 2024
Research, Employment, Plan, Novartis, Patient, Biostatistics, Microglia, Columbia University, University, Head, Senior, Drug, Therapy, Novartis Gene Therapies, Translational medicine, Bangladesh Technical Education Board, DSM-IV codes, Pharmaceutical industry

WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer.

Key Points: 
  • WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer.
  • "Dr. Kaufmann brings a wealth of experience that will be invaluable to the Vigil team,” said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil.
  • “As we further the development of both iluzanebart and VG-3927, we will benefit from her extensive background in neurological and rare diseases, as well as her proven expertise in both domestic and global drug development.”
    Dr. Kaufmann is an accomplished biotech executive joining Vigil Neuroscience from Affinia Therapeutics where she served as Chief Medical Officer leading medical, clinical, patient advocacy and regulatory strategy.
  • “I am honored and excited to join Vigil, a company at the forefront of developing innovative treatments for rare and common neurological diseases,” said Petra Kaufmann, M.D., M.S., F.A.A.N, Chief Medical Officer of Vigil.

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

Retrieved on: 
Wednesday, March 13, 2024
Microglia, American Academy, American Academy of Neurology, ALSP, AAN, Poster

WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting taking place on April 13-18, 2024 in Denver, Colorado and virtually.

Key Points: 
  • WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting taking place on April 13-18, 2024 in Denver, Colorado and virtually.
  • Details of the oral presentation are as follows:
    Title: Interim Results on VGL101 From IGNITE: First Interventional Phase 2 Study in Patients with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
    Details of the poster presentations are as follows:
    Presented by: David S. Lynch, M.D., Ph.D., National Hospital for Neurology & Neurosurgery; University College London Institute of Neurology

Cerevance Announces Presentation at Alzheimer’s Research UK Conference

Retrieved on: 
Wednesday, March 13, 2024
Brain, Conference, ALS, Central nervous system, CNS, Microglia, NLRP3, KCNK13, Frontotemporal dementia, Poster, Therapy, Neuroinflammation, FTD

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a poster at the upcoming Alzheimer’s Research UK Conference, taking place in Liverpool, United Kingdom, March 20-21, 2024.

Key Points: 
  • BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a poster at the upcoming Alzheimer’s Research UK Conference, taking place in Liverpool, United Kingdom, March 20-21, 2024.
  • Overview: Cerevance’s NETSseq platform enables the identification of novel targets, such as KCNK13 (THIK1), from specific cell types in the human brain.
  • Following the discovery of KCNK13, Cerevance has developed CVN293, a novel compound that selectively inhibits KCNK13 and reduces the release of IL-1β from microglia dependent on NLRP3.
  • CVN293 shows promise in potentially addressing CNS conditions characterized by neuroinflammation, such as frontotemporal dementia (FTD), Amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease.

Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days

Retrieved on: 
Tuesday, March 12, 2024
Webcast, Microglia

WATERTOWN, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President will participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Tuesday, March 19th at 3:30 p.m. E.T.

Key Points: 
  • WATERTOWN, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President will participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Tuesday, March 19th at 3:30 p.m. E.T.
  • To register for the live event, please click here .
  • The webcast will also be available on the Company’s website on the “Events & Presentations” page in the “Investors” section.
  • An archived webcast will be available for approximately 90 days following the presentation.

Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024

Retrieved on: 
Wednesday, March 6, 2024
Molecule, TREM2, Vigil, Pharmacology, Doctor of Philosophy, Microglia, Conference, Drug

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented preclinical data on the profile of VG-3927 in an oral presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases being held March 5 – March 9 in Lisbon Portugal.

Key Points: 
  • WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented preclinical data on the profile of VG-3927 in an oral presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases being held March 5 – March 9 in Lisbon Portugal.
  • The presentation outlines preclinical data on the agonist pharmacology of VG-3927, its effect on AD-associated neuropathological endpoints, and its potential as a disease-modifying therapeutic for the treatment of AD.
  • “As the first and only small molecule TREM2 agonist to enter clinical development, we are thrilled to have an opportunity to further demonstrate the differentiated profile for VG-3927 and how it could represent a significant treatment advancement for those living with AD,” said David Gray, PhD, Chief Science Officer at Vigil.
  • “Having recently commenced dosing in our Phase 1 healthy volunteer clinical trial evaluating VG-3927, we look forward to further investigating this mechanism of action and its potential as a disease-modifying therapeutic.”
    Title: Characterization of the First Small Molecule TREM2 Agonist, VG-3927, for Clinical Development in Alzheimer’s Disease

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease

Retrieved on: 
Tuesday, March 5, 2024
Mass, Mass General Brigham, DSM-IV codes, FDA, Hospital, Bleeding, Edema, Conference, Protein, Microglia, Research, Human, Pharmaceutical industry

AD/PD is the annual International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Lisbon, Portugal.

Key Points: 
  • AD/PD is the annual International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Lisbon, Portugal.
  • Our research has demonstrated that intranasal rodent anti-CD3 mAb and intranasal fully human anti-CD3 mAb (foralumab) will decrease microglia activation in rodents and humans, respectively.
  • Nasal anti-CD3 has also shown to reduce hemorrhage and edema that occurs with ARIA.”
    “With the focus on effective Alzheimer’s disease treatments and we have the potential to be a novel, first in class neuroinflammatory modulator,” commented Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences.
  • The data also excitingly shows a reduction of hemorrhage and edema that occurs with ARIA.”

Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024

Retrieved on: 
Thursday, February 29, 2024
CSF1R, ALSP, Genetic testing, Approximation error, Neurodegenerative disease, Life, Multiple sclerosis, Patient, Disease, Senior counsel, Diagnosis, Microglia, Research, Medical device

WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) --  Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented a poster detailing the impact of misdiagnosis and the importance of genetic testing at the 2024 ACTRIMS Forum being held in West Palm Beach, Florida, from February 29 – March 2.

Key Points: 
  • “We continue to hear from members of the ALSP community that the path to an accurate diagnosis can be difficult, indirect, and time consuming.
  • As with many rare diseases, the misdiagnosis of ALSP can be a significant and persistent challenge to overcome.
  • It also showed that when considering genetic testing, access to approved treatments may be a motivator for patients, family members, and clinicians.
  • A structured patient journey workshop was hosted as a means of better understanding life with ALSP, including the impact of misdiagnosis and barriers to genetic testing.

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024
PD, GSK, Arnon Rosenthal, Investment, Interest, ARIA, AbbVie, Webcast, Plasma, PET, MRI, Central nervous system, Traffic barrier, GPNMB, Cerebrospinal fluid, Breakthrough therapy, ALEC, Frontotemporal dementia, FTD, DSM-IV codes, European Medicines Agency, Food and Drug Administration, Canadian International Council, Brain, SAN, Total, LTE, Amyloid-related imaging abnormalities, Alector, ALS, AAIC, PROGRESS, ABC, Manuscript, Conference, Safety, Biomarker, Patent, CSF, Mutation, IND, Microglia, European Patent Convention, Insurance, PIN, FDA, Food, Risk, TREM2, Dementia, Disease, Pharmaceutical industry

Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.

Key Points: 
  • Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.
  • In September 2023, Alector completed enrollment of 381 participants in the randomized, double-blind, placebo-controlled, dose-ranging, INVOKE-2 Phase 2 clinical trial.
  • In July 2023, Alector presented an update on INVOKE-2 at the Alzheimer’s Association International Conference (AAIC).
  • Alector’s management team will host a conference call discussing Alector’s results for the fourth quarter and full year 2023 and provide a business update.